Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHARMACOKINETIC (PK) DRUG-DRUG INTERACTION BETWEEN SAMATASVIR (IDX719), A PAN-GENOTYPIC NS5A INHIBITOR, AND SIMEPREVIR IN HEALTHY VOLUNTEERS AND HCV-INFECTED SUBJECTS

Trial Profile

PHARMACOKINETIC (PK) DRUG-DRUG INTERACTION BETWEEN SAMATASVIR (IDX719), A PAN-GENOTYPIC NS5A INHIBITOR, AND SIMEPREVIR IN HEALTHY VOLUNTEERS AND HCV-INFECTED SUBJECTS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Samatasvir (Primary) ; Simeprevir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Idenix Pharmaceuticals; Janssen
  • Most Recent Events

    • 15 May 2014 New trial record
    • 09 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top